Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$258 Mln
Revenue (TTM)
$37 Mln
Net Profit (TTM)
$0 Mln
ROE
-1 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
9.5
Industry P/E
--
EV/EBITDA
-7.1
Div. Yield
0 %
Debt to Equity
2.1
Book Value
$1
EPS
$-0.9
Face value
--
Shares outstanding
29,663,875
CFO
$-85.57 Mln
EBITDA
$-92.00 Mln
Net Profit
$-103.93 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Clearpoint Neuro Inc (CLPT)
| -31.5 | -25.5 | -31.5 | -28.4 | 3.5 | -15.4 | -2.8 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Clearpoint Neuro Inc (CLPT)
| -11.1 | 125.0 | -19.8 | -24.5 | -29.4 | 231.0 | 205.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Clearpoint Neuro Inc (CLPT)
|
9.4 | 257.6 | 37.0 | -25.5 | -65.7 | -95.6 | -- | 9.5 |
| 7.9 | 5,176.8 | 6,552.2 | -530.2 | -4.1 | -9.2 | -- | 0.9 | |
| 36.8 | 5,222.6 | 3,436.5 | -8.6 | 2.2 | -0.4 | -- | 2.1 | |
| 112.8 | 6,098.9 | 507.4 | -187.7 | -36.2 | -26.4 | -- | 8.9 | |
| 76.1 | 4,758.4 | 1,541.6 | 233.6 | 21.6 | 21.4 | 21.4 | 4.5 | |
| 178.6 | 9,411.8 | 1,526.9 | -151.5 | 20.0 | -17.1 | -- | 12.9 | |
| 67.7 | 4,079.4 | 1,515.9 | 128.5 | 13.0 | 8.7 | 32.2 | 2.5 | |
| 330.4 | 12,879.6 | 1,403.7 | 177.7 | 14.7 | 13.8 | 72.5 | 9.2 | |
| 117.8 | 6,280.4 | 738.3 | 48.9 | 11.4 | 2.4 | 129.6 | 3.0 | |
| 32.1 | 13,409.8 | 6,178.4 | 626.5 | 13.0 | 11.9 | 22.1 | 2.6 |
ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint... systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula. It also provides ClearPoint software, which guides the physician in surgical planning, device alignment, navigation to the target, and procedure monitoring; ClearPoint Prism Neuro laser therapy system to necrotize or coagulate soft tissue; and IRRAflow system, an active fluid exchange platform. In addition, the company offers consulting services to its pharmaceutical and other medical technology partners, such as benchtop testing, preclinical studies, clinical trial support, regulatory consultation, and translation from the preclinical to the clinical setting. It has licenses and collaboration agreements with Koninklijke Philips N.V., UCB Biopharma SRL, Clinical Laserthermia Systems AB, University of California, San Francisco, and NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California. Address: 120 S. Sierra Avenue, Solana Beach, CA, United States, 92075 Read more
President, CEO & Director
Mr. Joseph Michael Burnett
President, CEO & Director
Mr. Joseph Michael Burnett
Headquarters
Solana Beach, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Clearpoint Neuro Inc (CLPT) is $9.37 (NASDAQ) as of 02-Apr-2026 19:59 EDT. Clearpoint Neuro Inc (CLPT) has given a return of 3.55% in the last 3 years.
Since, TTM earnings of Clearpoint Neuro Inc (CLPT) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-15.00
|
13.67
|
|
2024
|
-21.96
|
16.36
|
|
2023
|
-7.68
|
8.02
|
|
2022
|
-12.37
|
5.51
|
|
2021
|
-16.35
|
4.83
|
The 52-week high and low of Clearpoint Neuro Inc (CLPT) are Rs 30.10 and Rs 8.60 as of 04-Apr-2026.
Clearpoint Neuro Inc (CLPT) has a market capitalisation of $ 258 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Clearpoint Neuro Inc (CLPT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.23
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.